Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

NORTH CHICAGO, Ill. , June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.

AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Enphase Energy

Johnson & Johnson

Norwegian Cruise Line

PepsiCo

Pfizer

SoFi Technologies

The financial media does its best to keep you informed about what's happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards.

7 Overlooked Stocks That Belong in Every Portfolio

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?

AstraZeneca

Vertex Pharmaceuticals

AbbVie covers all the bases for investors -- income, value, and growth. AstraZeneca is an inexpensive stock that has solid growth opportunities.

3 No-Brainer Stocks to Buy in June

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2 In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2 UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine. It can lead to a substantial burden and often results in disability3-6 NORTH CHICAGO, Ill.

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie stock has fallen into a correction, declining nearly 16% from its March 2024 highs. Despite the pullback, AbbVie remains a highly profitable company with a strong portfolio and robust long-term guidance. The stock valuation is not cheap, but ABBV's 4% dividend yield may provide valuation support.

AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)

AbbVie, a key player in my dividend growth portfolio, boasts a strong 4% yield and a consistent record of annual hikes. Its robust product lineup and innovative pipeline promise growth. Despite losing Humira's patent, AbbVie's new drugs, Skyrizi and Rinvoq, drive impressive revenue growth. The company continues to outperform the market with a solid return profile. Trading at a reasonable P/E ratio, AbbVie combines growth potential and reliable income.

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs).

AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform

Arcellx

Agenus

BridgeBio Pharma Inc

Coya Therapeutics Inc

CRISPR Therapeutics

Novo Nordisk

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.

7 Biotech Stocks to Put on Your Breakthrough Radar

Nvidia's high valuation could make the stock vulnerable to a sell-off if the company fall short of expectations. AbbVie is a top healthcare company with underrated growth prospects.

Forget Nvidia, Buy This Magnificent Healthcare Stock Instead

Lamb Weston Hlds

JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical issues, infrastructure spending, and large deficits/debt levels. The favorable period for inflation in developed nations from 2009 to 2021 is likely over.

High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right Now

Landos Biopharma

-   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill. , May 23, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP).

AbbVie Completes Acquisition of Landos Biopharma

Eli Lilly

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine.

3 Biotech Stocks to Buy on the Dip: May 2024

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why AbbVie (ABBV) is a Top Value Stock for the Long-Term

This company offers growth, high yield, and dividend growth.

A Must-Own Stock for Any Portfolio

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel.

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel

AbbVie is bolstering its psychiatry pipeline with an acquisition. The biotech it's acquiring is developing psychedelic-adjacent drugs.

2 Billion More Reasons to Buy AbbVie Stock

Amazon

Walmart

Since 1928, there have been 25 bear markets, or declines in the S&P 500 of 20% or more, according to Yardeni Research. Market corrections have been far more common.

3 S&P 500 Stocks That Have Proven Themselves Recession-Proof

AbbVie's lead drug Humira lost its patent-protected market exclusivity in the U.S. last year. Despite shrinking Humira revenues, AbbVie's first-quarter sales grew thanks to more recently launched blockbusters.

1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?

-    AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD) -    Data to be presented from the SEQUENCE head-to-head trial comparing risankizumab (SKYRIZI®) versus ustekinumab (STELARA®) in Crohn's disease include an economic analysis and oral presentation that assessed inflammation biomarkers -    Additional presentations include efficacy and safety data evaluating clinical, endoscopic, and histologic outcomes from both the INSPIRE Phase 3 induction study and the COMMAND Phase 3 maintenance study of risankizumab as a therapy for adults with moderately to severely active ulcerative colitis NORTH CHICAGO, Ill. , May 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced it is presenting 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, being held May 18-21 in Washington, D.C.

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

Boeing

CVS Health

Lockheed Martin

Procter & Gamble

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

7 Value Stocks to Buy and Hold for a Decade of Dominance

Chevron

Essential Utilities

What could be better than well-established retirement stocks to buy that you can trust? How about adding to that confidence level with the backing of Wall Street analysts.

Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024

AbbVie, Inc. (NYSE:ABBV ) Bank of America Health Care Conference Call May 15, 2024 1:40 PM ET Company Participants Robert Michael - CEO Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics Jeffrey Stewart - COO Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Operator Geoffrey Meacham With me on stage is CEO, Rob Michael, currently President and COO, I guess, but soon to be. Robert Michael Soon to be, yes.

AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript

Ally Financial

Comcast

Camden Property

Cisco Systems

Discover

DHL Group

Dow Inc

Elevance Health Inc

First American Financial

MetLife

Merck

Nucor

Teleperformance

The April/May 2024 edition of Fortune Magazine revealed its 100 Best Companies To Work For, or Besties. My latest Dogcatcher-quest to sniff-out the best dividend-buys found 56 dividend-paying Besties using YCharts 5/13/24 data.

2 Fortune 100 Best Co's To Work For Are Also Good To Own

News for AbbVie Stock (ABBV)